United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $499.03, for a total transaction of $4,740,785.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares […]

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CEO Sanjiv Patel sold 48,199 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.94, for a total value of $912,889.06. Following the transaction, the chief executive officer directly owned 519,500 shares in the company, […]

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $87.29, for a total value of $1,309,350.00. Following the sale, the chief executive officer directly owned 552,540 shares of the company’s […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $493.46, for a total value of $4,687,870.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in […]

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) CEO Lawrence Otto Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer owned 925,580 shares of […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the […]